A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, have achieved good efficacy in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients, but eventual drug resistance is inevitable. Thus, new TKI-based combination therapies sho...

Full description

Bibliographic Details
Main Authors: Wanjun Yu, Fei Ye, Xiao Yuan, Yali Ma, Chaoming Mao, Xiaoqin Li, Jian Li, Chunhua Dai, Fenhong Qian, Junrong Li, Xiujuan Fan, Yuepeng Zhou, Deqiang Wang, Zhenhong Guo, Huazhang An, Minghui Zhang, Deyu Chen, Sheng Xia
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Non-small-cell lung cancer
Natural killer T cell
Immunotherapy
Gefitinib
Randomized controlled trial
Online Access:https://doi.org/10.1186/s12885-021-08590-1

Internet

https://doi.org/10.1186/s12885-021-08590-1

Similar Items